B-cell maturation antigen (BCMA) is the target of chimeric antigen receptor (CAR) T-cell therapy, which has become a game-changing treatment for multiple myeloma, a cancer often associated with bone disease. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.